Theleme Partners LLP MRNA — MODERNA INC

Ownership history in Theleme Partners LLP  ·  34 quarters on record

AI Ownership Summary

Theleme Partners LLP reported MODERNA INC (MRNA) in 34 quarterly 13F filings from 2023 Q4 through 2025 Q4. Peak portfolio weight reached 41.17% in 2024 Q2. The latest visible filing shows MRNA at 15.52% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this MRNA ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Theleme Partners LLP's position in MODERNA INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

MRNA was reported at 15.52% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
41.17% in 2024 Q2

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

MRNA stock page Theleme Partners LLP fund profile Theleme Partners LLP full holdings
How Theleme Partners LLP held MRNA — position size vs. price
% of Fund (quarterly)    MRNA price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 13 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 ADDED — — — 8,081,810 +13,000 +0.2% 15.52% $238.3M 2026-02-14 (Est.) $42.23
2025 Q3 ADDED — — — 8,068,810 +200,000 +2.5% 13.32% $208.4M 2025-11-13 $24.96
2025 Q2 ADDED — — — 7,868,810 +626,420 +8.6% 13.20% $217.1M 2025-08-14 $26.69
2025 Q1 REDUCED — — — 7,242,390 -64,471 -0.9% 16.14% $205.3M 2025-05-15 $23.65
2024 Q4 ADDED — — — 7,306,861 +7,298,889 +91556.6% 20.36% $303.8M 2025-02-14 $32.99
2024 Q3 REDUCED 99.9% -41.1% ✅ 7,972 -7,218,889 -99.9% 3.05% $53.3M 2024-11-14 $39.77
2024 Q3 ADDED — — — 7,226,861 +7,220,657 +116387.1% 27.61% $483.0M 2024-11-14 $39.77
2024 Q2 REDUCED 99.9% -43.7% ✅ 6,204 -7,220,657 -99.9% 3.54% $73.7M 2024-08-14 $82.25
2024 Q2 ADDED — — — 7,226,861 +5,786,861 +401.9% 41.17% $858.2M 2024-08-14 $82.25
2024 Q1 REDUCED 80.3% +8.8% ❌ 1,440,000 -5,881,797 -80.3% 7.78% $153.4M 2024-05-14 $128.32
2024 Q1 ADDED — — — 7,321,797 +5,307,797 +263.5% 39.54% $780.2M 2024-05-14 $128.32
2023 Q4 REDUCED 72.6% +6.2% ❌ 2,014,000 -5,335,456 -72.6% 9.55% $200.3M 2024-02-13 $85.37
2023 Q4 ADDED — — — 7,349,456 +451,844 +6.6% 34.86% $730.9M 2024-02-13 $85.37
21 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

🏢 Other funds also holding MRNA

As of 2026 Q1 — sorted by position size

Green Alpha Advisors, LLC 3Y 1.72% CHAPIN DAVIS, INC. 3Y 1.42% Legal Advantage Investments, Inc. 3Y 1.26% BANQUE PICTET & CIE SA 3Y 7Y 0.98% Douglas Lane & Associates, LLC 3Y 7Y 0.96% PATTON FUND MANAGEMENT, INC. 3Y 0.76% Leonteq Securities AG 0.57% Friedenthal Financial 3Y 7Y 0.55% Blue Sky Capital Consultants Group, Inc. 0.5% WESPAC Advisors, LLC 3Y 7Y 0.43%

FAQ About Theleme Partners LLP and MRNA

These are the practical questions this page is built to answer before you even open the full history table.

How long has Theleme Partners LLP reported owning MRNA?

Theleme Partners LLP reported MRNA across 13 quarterly 13F filings, from 2023 Q4 through 2025 Q4.

What was the largest reported MRNA position in Theleme Partners LLP's portfolio?

The largest reported portfolio weight for MRNA was 41.17% in 2024 Q2.

What is the latest reported MRNA position on this page?

The most recent filing on this page is 2025 Q4, when Theleme Partners LLP reported 8,081,810 shares, equal to 15.52% of portfolio, with an estimated market value of $238.3M.

What does the chart on this MRNA ownership page compare?

The chart compares Theleme Partners LLP's quarterly MRNA portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Theleme Partners LLP time their MRNA position?

Based on 13F filing dates vs. subsequent MRNA price moves, Theleme Partners LLP correctly timed 18 out of 33 reported position changes (55%). The annualised alpha on MRNA relative to SPY over the holding period was -3.5%.

← Back to Theleme Partners LLP Holdings